Key insights
- Novavax (NVAX) shares rose after reporting better-than-expected Q1 2026 results, with a narrower loss and higher revenue than anticipated. The company's focus on partnerships and the potential of its Matrix-M technology in various fields contributed to investor optimism. While past performance doesn't guarantee future results, the positive earnings surprise suggests a potential turnaround for the company.
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.
The biotechnology firm posted a loss of 6 cents per share, which was significantly narrower than the consensus estimate of a 25-cent loss. Quarterly revenues totaled $139.5 million, easily surpassing the expected $69.5 million. While sales were down 79% compared to the same period in the previous year, investors focused on the strong performance relative to expectations.
The company also highlighted that its business is increasingly tied to partners, who now have the rights to evaluate its proprietary Matrix-M technology in over 30 fields, including infectious diseases and oncology, signaling potential for future growth.
Is now the time to buy Novavax? Access our full analysis report here, it’s free.
Novavax’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. But moves this big are rare even for Novavax and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 2 months ago when the stock gained 24.4% on the news that the company reported fourth-quarter financial results that significantly beat analyst expectations.
Novavax announced revenue of $147.1 million, up approximately 67% from the prior year's quarter and well ahead of forecasts. The company also posted a surprise profit with earnings per share (EPS) of $0.11. This was a significant beat, as analysts had expected a loss of $0.49 per share, and it marked a notable turnaround from a loss of $0.51 per share in the same period of the previous year. The strong top-line growth and unexpected profitability drove investor optimism.
Novavax is up 47% since the beginning of the year, and at $10.48 per share, it is trading close to its 52-week high of $11.19 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at only $65.28.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.